Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 6/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162587 | 1.00 | HTR1A (0.50) | HTR1ASLC6A2SLC6A4SLC6A3PIM1 | |
| SCHEMBL5160669 | 0.92 | HTR1A (0.56) | HTR1ASLC6A2SLC6A4SLC6A3PIM1 | |
| SCHEMBL5160666 | 0.92 | HTR1A (0.56) | HTR1ASLC6A2SLC6A4SLC6A3PIM1 | |
| SCHEMBL5160207 | 0.90 | HTR1A (0.49) | HTR1ASLC6A2SLC6A4SLC6A3PIM1 | |
| SCHEMBL5160210 | 0.90 | HTR1A (0.49) | HTR1ASLC6A2SLC6A4SLC6A3PIM1 | |
| SCHEMBL5160763 | 0.87 | HTR1A (0.54) | HTR1ASLC6A2SLC6A4SLC6A3PIM1 | |
| SCHEMBL5160756 | 0.87 | HTR1A (0.54) | HTR1ASLC6A2SLC6A4SLC6A3PIM1 | |
| SCHEMBL5160086 | 0.87 | SLC6A2 (0.47) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5160082 | 0.87 | SLC6A2 (0.47) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5160693 | 0.87 | HTR1A (0.48) | HTR1ASLC6A2SLC6A4SLC6A3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2006-03-09 | — | — | US | claimed |
| WO-2005053701-A1 | COMBINATION OF DOPAMINE AGONISTS AND ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER PRODUCTS INC. (US) | 2005-06-16 | — | — | WO | claimed |
| EP-0929528-B1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER (US) | 2003-07-23 | — | — | EP | claimed |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| US-6423708-B1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2002-07-23 | — | — | US | claimed |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | claimed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | claimed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | HTR1A 1064/4885SLC6A2 4351/4885SLC6A4 4583/4885 |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | HTR1A 1064/4885SLC6A2 4351/4885SLC6A4 4583/4885 |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | HTR1A 1064/4885SLC6A2 4351/4885SLC6A4 4583/4885 |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | HTR1A 797/4885SLC6A2 4180/4885SLC6A4 4503/4885 |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | DRD2, OPRL1, SLC6A3 | HTR1A 124/4885SLC6A2 20/4885SLC6A4 107/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | HTR1A 1/4885SLC6A2 39/4885SLC6A4 36/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | HTR1A 1064/4885SLC6A2 4351/4885SLC6A4 4583/4885 |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | HTR1A 1064/4885SLC6A2 4351/4885SLC6A4 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.